44
Participants
Start Date
November 30, 2006
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Capecitabine, Oxaliplatin, Cetuximab
Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
Asan Medical Center, Seoul
Korea Cancer Center Hospital, Seoul
Seoul Samsung Medical Center, Seoul
Lead Sponsor
Asan Medical Center
OTHER